Home / Generics / Research

Research

Patients’ perceptions of HIV generics in France

In a study of patient perceptions of HIV generics in France, Jacomet and co-authors found that while the majority of patients accepted antiretroviral generics, a third of the patients were openly opposed to antiretroviral generics [1].

Patients’ and physicians’ perceptions of HIV generics

A study of adult HIV positive outpatients and their physicians in clinics across France found that a third of patients and a quarter of physicians are openly opposed to antiretroviral generics [1].

Statin generics improves adherence

Switching from a brand-name statin to a generic statin has been shown to improve adherence, researchers in Sweden report [1].

Poland’s experience with generic imatinib

In July 2014, Poland became the first country in the European Union (EU) to introduce a generic form of the chronic myeloid leukaemia (CML) treatment imatinib. This, and the dearth of reliable information related to CML patients in Europe who have taken generic imatinib, make the country uniquely positioned to monitor the process of switching from the brand-name drug to its generic, according to author Patrycja Rusicka of the Medical University of Warsaw, Poland [1].

Safety and cost considerations of generic and originator gabapentin

The launch of generic garbapentin prompted researchers from the Chulalongkorn University and the King Chulalongkorn Memorial Hospital in Bangkok, Thailand, to carry out a study to compare the safety and effectiveness of generic gabapentin compared to originator gabapentin (Neurontin) [1].

Brazilian patients positive about generics

A study looking at patients perceptions on generics in Brazil concludes that, although Brazilian patients have a positive attitude towards generics, more work is needed to increase the use of generics in the country.

Effectiveness of generic and originator gabapentin in lower back pain

Researchers from the Chulalongkorn University and the King Chulalongkorn Memorial Hospital in Bangkok, Thailand, carried out a study to compare the effectiveness of generic gabapentin Sandoz compared to originator gabapentin (Neurontin) [1].

Comparison of generic and originator gabapentin

The cost of treatment for patients with neuropathic lower back pain is higher than those with non-neuropathic lower back pain. Originator gabapentin (Neurontin), an anticonvulsant, the efficacy has been proven for pain improvement among patients with neuropathic pain. In Thailand, gabapentin has usually been prescribed for patients having chronic back pain associated with lumbar radiculopathy, however, the high cost of originator gabapentin (Neurontin) has been found to be a problem for patients. Although generic gabapentin has recently been launched in Thailand, there is limited clinical evidence to prove its effectiveness compared to the originator.

Generics utilization policies necessary to sustain Medicaid

A review of the history and expansion of generics utilization policies and their critical role in the US Medicaid system in an era of reduced budgets concluded that such policies are a necessary component for preservation of the Medicaid system [1].

Potential savings of Euros 72 million with more generics use in three therapeutic areas

A nationwide cohort study in Austria reported that substituting branded medications with drugs containing the same active ingredients (generics) could save considerable amounts of money. A study at the Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS) at the Medical University of Vienna, Austria, in cooperation with the Main Association of Austrian Social Security Institutions, has calculated the potential savings from generic medications used in the treatment of common conditions such as hypertension, hyperlipidaemia and diabetes mellitus. The potential annual financial savings for health insurance companies stand at around 18 per cent, equating to tens of millions of Euros [1].

Generics News Research General

more

Biosimilars News Research General

more